Atallah, E. L., Broder, M. S., Chan, O., Dalglish, H., Flynn, K. E., Gilreath, J., … Yang, J. (2024). U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML). In Blood (Vol. 144, pp. 5052–5052). American Society of Hematology. https://doi.org/10.1182/blood-2024-194617

Atallah, Ehab L., Michael S. Broder, Onyee Chan, Hannah Dalglish, Kathryn E. Flynn, Jeffrey Gilreath, Marisa Hine, et al. “U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML).” In Blood, 144:5052–5052. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-194617.

Atallah EL, Broder MS, Chan O, Dalglish H, Flynn KE, Gilreath J, et al. U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML). In: Blood. American Society of Hematology; 2024. p. 5052–5052.

Atallah, Ehab L., et al. “U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML).” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 5052–5052. Crossref, doi:10.1182/blood-2024-194617.

Atallah EL, Broder MS, Chan O, Dalglish H, Flynn KE, Gilreath J, Hine M, Hunter AM, Mauro MJ, Pinilla-Ibarz J, Rein LAM, Shah NP, Stemper E, Tantravahi SK, Yang J. U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML). Blood. American Society of Hematology; 2024. p. 5052–5052.